search button

Susceptibility of XPD and hOGG1 genetic variants to prostate cancer

  • Authors:
    • Cheng Zhou
    • Li‑Ping Xie
    • Yi‑Wei Lin
    • Kai Yang
    • Qi‑Qi Mao
    • Yue Cheng

  • View Affiliations

  • Published online on: May 30, 2013     https://doi.org/10.3892/br.2013.123
  • Pages: 679-683
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

DNA repair genes are important in maintaining genomic stability and integrity. DNA repair gene polymorphisms, such as those of the human homolog of 8‑oxoguanine DNA glycosylase 1 (hOGG1) and excision repair cross‑complementing rodent repair deficiency, complementation group 2̸Xeroderma pigmentosum complementation group D (ERCC2̸XPD), contribute to carcinogenesis. The aim of this study was to investigate the association of prostate cancer (PCa) risk with hOGG1 and ERCC2̸XPD genetic variants. A case‑control study of 200 cases including 100 PCa patients and 100 healthy subjects was conducted. Two single‑nucleotide polymorphisms (SNPs) (ERCC2/XPD Arg156Arg and hOGG1 Ser326Cys) were genotyped by polymerase chain reaction‑restriction fragment length polymorphism (PCR‑RFLP). The results demonstrated a significant association of the XPD156 homozygous (AA, OR=3.80; 95% CI: 1.19‑12.18; P=0.017), heterozygous (AC, OR=2.48; 95% CI: 1.02‑6.35; P=0.033) and combined (AA+AC, OR=2.76; 95% CI: 1.18‑6.84; P=0.011) mutant genotypes with a predisposition to high‑risk PCa. In the stratified analysis, predisposition to high‑risk PCa was also associated with the mutant genotypes of hOGG1 326 homozygous mutant (GG, OR=2.93; 95% CI: 1‑8.74; P=0.033). The results also showed that the A allele of XPD Arg156Arg and the G allele of hOGG1 Ser326Cys were associated with an increased risk of PCa (OR=1.86 and 1.62; 95% CI: 1.13‑3.06 and 1‑2.67, respectively). In conclusion, the findings of this study demonstrated that the ERCC2/XPD Arg156Arg and hOGG1 Ser326Cys polymorphisms increased the susceptibility to high‑risk PCa.
View Figures
View References

Related Articles

Journal Cover

July-August 2013
Volume 1 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.3
  • Ranked
    (total number of cites)
  • CiteScore: 3.7
  • CiteScore Rank: Q2: #23/79 Pharmacology, Toxicology and Pharmaceutics
  • Source Normalized Impact per Paper (SNIP): 0.742
  • SCImago Journal Rank (SJR): 0.488
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou C, Xie LP, Lin YW, Yang K, Mao QQ and Cheng Y: Susceptibility of XPD and hOGG1 genetic variants to prostate cancer. Biomed Rep 1: 679-683, 2013
APA
Zhou, C., Xie, L., Lin, Y., Yang, K., Mao, Q., & Cheng, Y. (2013). Susceptibility of XPD and hOGG1 genetic variants to prostate cancer. Biomedical Reports, 1, 679-683. https://doi.org/10.3892/br.2013.123
MLA
Zhou, C., Xie, L., Lin, Y., Yang, K., Mao, Q., Cheng, Y."Susceptibility of XPD and hOGG1 genetic variants to prostate cancer". Biomedical Reports 1.4 (2013): 679-683.
Chicago
Zhou, C., Xie, L., Lin, Y., Yang, K., Mao, Q., Cheng, Y."Susceptibility of XPD and hOGG1 genetic variants to prostate cancer". Biomedical Reports 1, no. 4 (2013): 679-683. https://doi.org/10.3892/br.2013.123